Prognostic value of myeloid-derived suppressor-like cells in acute myeloid leukemia: insights from immunophenotyping and clinical correlations.

Autor: Sant'Ana AN; Laboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil.; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil., Dias CK; Laboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil.; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil., Nunes VBS; Laboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil.; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil., Farias MG; Unidade de Hematologia e Citometria de Fluxo, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil., Alegretti AP; Setor de Inovação, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil., Portela P; Unidade de Hematologia e Citometria de Fluxo, Serviço de Diagnóstico Laboratorial, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil., Calvache ET; Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil., Meirelles MF; Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil., Daudt LE; Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil.; Programa de Pós-Gradução em Saúde da Criança e do Adolescente, UFRGS, Porto Alegre, RS, 90035-003, Brazil., Michalowski MB; Programa de Pós-Gradução em Saúde da Criança e do Adolescente, UFRGS, Porto Alegre, RS, 90035-003, Brazil.; Serviço de Oncologia Pediátrica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil., Paz AA; Serviço de Hematologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, 90035-903, Brazil., Figueiró F; Laboratório de Imunobioquímica do Câncer, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil. fabricio.figueiro@ufrgs.br.; Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, UFRGS, Porto Alegre, RS, 90035-003, Brazil. fabricio.figueiro@ufrgs.br.
Jazyk: angličtina
Zdroj: Immunologic research [Immunol Res] 2024 Dec 14; Vol. 73 (1), pp. 11. Date of Electronic Publication: 2024 Dec 14.
DOI: 10.1007/s12026-024-09558-6
Abstrakt: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population that acts on both innate and adaptive immunity, fostering immune escape in tumors and contributing to cancer progression. Despite the lack of definitive markers for immunophenotyping MDSCs, particularly the polymorphonuclear (PMN-MDSC) subset, these cells seem to play a crucial role in acute myeloid leukemia (AML) patients' prognosis. Additionally, the maturation stage of MDSCs remains a subject of debate and is largely unknown within the AML context. In this study, we conducted a retrospective analysis of flow cytometry immunophenotyping data obtained at the diagnosis of AML patients. We explored how the enrichment of neutrophil maturation stages, the frequency of PMN-MDSC-like cells and monocytic MDSC-like population (M-MDSC-like), and the ratios of MDSC-like cells to T lymphocytes correlate with relevant prognostic indicators. Our findings revealed that CD45 + CD33 low HLA-DR - CD36 + PMN-MDSC-like cells and mature CD13 + CD11b + CD10 + neutrophils correlate poor survival in AML patients. Furthermore, PMN-MDSC-like cells, and their ratio to T lymphocytes, are elevated in patients with adverse-risk stratification. Similarly, the M-MDSC-like population is increased in FLT3-ITD mutation carrier patients. Notably, we observed confirmational evidence of CD36 relevance in the AML context, which has emerged recently as a potential marker for PMN-MDSCs. Our study highlights significant findings associating increased MDSC-like subsets and poor prognostic factors in AML.
Competing Interests: Declarations. Ethics approval: This retrospective study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional and National Ethics Review Boards (project nº 2021–0512; CAAE n° 53043421700005327) approved this study. Consent to participate: Informed consent was obtained from all individual participants included in the study. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: